Zacks: Analysts Anticipate PRA Health Sciences Inc (NASDAQ:PRAH) to Announce $1.29 Earnings Per Share

Analysts expect that PRA Health Sciences Inc (NASDAQ:PRAH) will report earnings of $1.29 per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for PRA Health Sciences’ earnings. The lowest EPS estimate is $1.26 and the highest is $1.30. PRA Health Sciences posted earnings of $1.13 per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 14.2%. The company is expected to issue its next earnings report on Wednesday, October 30th.

On average, analysts expect that PRA Health Sciences will report full-year earnings of $5.05 per share for the current year, with EPS estimates ranging from $5.00 to $5.10. For the next fiscal year, analysts anticipate that the business will post earnings of $5.71 per share, with EPS estimates ranging from $5.66 to $5.75. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that cover PRA Health Sciences.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Wednesday, July 31st. The medical research company reported $1.22 EPS for the quarter, topping the consensus estimate of $1.11 by $0.11. The company had revenue of $763.31 million during the quarter, compared to analyst estimates of $764.95 million. PRA Health Sciences had a net margin of 5.39% and a return on equity of 26.64%. PRA Health Sciences’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.00 earnings per share.

Several research analysts recently commented on PRAH shares. BidaskClub raised PRA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Leerink Swann started coverage on PRA Health Sciences in a research note on Tuesday, July 2nd. They issued a “market perform” rating and a $105.00 price objective for the company. Mizuho set a $100.00 price objective on PRA Health Sciences and gave the company a “hold” rating in a research note on Friday, May 3rd. Finally, Svb Leerink reissued a “market perform” rating on shares of PRA Health Sciences in a research note on Tuesday, July 2nd. Eight research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $113.40.

PRA Health Sciences stock traded up $1.97 during mid-day trading on Thursday, hitting $94.45. The company had a trading volume of 18,967 shares, compared to its average volume of 619,701. The company has a debt-to-equity ratio of 1.11, a current ratio of 0.99 and a quick ratio of 0.99. PRA Health Sciences has a 12-month low of $82.12 and a 12-month high of $121.98. The firm’s fifty day moving average is $98.26. The stock has a market cap of $6.11 billion, a P/E ratio of 24.12, a price-to-earnings-growth ratio of 1.29 and a beta of 1.12.

Several institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its stake in shares of PRA Health Sciences by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 6,371,495 shares of the medical research company’s stock worth $631,734,000 after acquiring an additional 78,746 shares during the last quarter. BlackRock Inc. increased its stake in shares of PRA Health Sciences by 0.9% in the 1st quarter. BlackRock Inc. now owns 6,211,391 shares of the medical research company’s stock worth $685,054,000 after acquiring an additional 52,524 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of PRA Health Sciences by 542.2% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 4,699,572 shares of the medical research company’s stock worth $465,963,000 after acquiring an additional 3,967,806 shares during the last quarter. FMR LLC grew its holdings in shares of PRA Health Sciences by 11.3% during the 1st quarter. FMR LLC now owns 2,881,740 shares of the medical research company’s stock worth $317,827,000 after purchasing an additional 292,887 shares during the period. Finally, AQR Capital Management LLC grew its holdings in shares of PRA Health Sciences by 11.2% during the 2nd quarter. AQR Capital Management LLC now owns 2,028,713 shares of the medical research company’s stock worth $194,655,000 after purchasing an additional 203,570 shares during the period. 97.98% of the stock is owned by institutional investors and hedge funds.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Story: Why is momentum important to successful trading?

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.